A detailed history of Avidity Partners Management LP transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Avidity Partners Management LP holds 790,000 shares of RVMD stock, worth $34.2 Million. This represents 2.2% of its overall portfolio holdings.

Number of Shares
790,000
Previous 755,000 4.64%
Holding current value
$34.2 Million
Previous $29.3 Million 22.16%
% of portfolio
2.2%
Previous 1.44%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$36.92 - $47.94 $1.29 Million - $1.68 Million
35,000 Added 4.64%
790,000 $35.8 Million
Q2 2024

Aug 14, 2024

BUY
$30.14 - $40.68 $3.62 Million - $4.88 Million
120,000 Added 18.9%
755,000 $29.3 Million
Q1 2024

May 15, 2024

BUY
$26.56 - $33.55 $15.3 Million - $19.3 Million
575,000 Added 958.33%
635,000 $20.5 Million
Q4 2023

Feb 14, 2024

SELL
$18.35 - $34.12 $11 Million - $20.4 Million
-597,200 Reduced 90.87%
60,000 $1.72 Million
Q3 2023

Nov 14, 2023

SELL
$25.17 - $35.05 $10.5 Million - $14.6 Million
-417,800 Reduced 38.87%
657,200 $18.2 Million
Q2 2023

Aug 14, 2023

SELL
$20.28 - $27.0 $5.47 Million - $7.28 Million
-269,800 Reduced 20.06%
1,075,000 $28.8 Million
Q1 2023

May 15, 2023

SELL
$20.76 - $30.09 $23.5 Million - $34 Million
-1,130,200 Reduced 45.66%
1,344,800 $29.1 Million
Q4 2022

Feb 14, 2023

BUY
$17.68 - $25.53 $2.72 Million - $3.93 Million
153,800 Added 6.63%
2,475,000 $59 Million
Q3 2022

Nov 14, 2022

BUY
$17.46 - $26.0 $17.4 Million - $25.9 Million
996,200 Added 75.18%
2,321,200 $45.8 Million
Q2 2022

Aug 15, 2022

BUY
$14.54 - $27.17 $19.3 Million - $36 Million
1,325,000 New
1,325,000 $25.8 Million

Others Institutions Holding RVMD

About Revolution Medicines, Inc.


  • Ticker RVMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,697,600
  • Market Cap $3.8B
  • Description
  • Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...
More about RVMD
Track This Portfolio

Track Avidity Partners Management LP Portfolio

Follow Avidity Partners Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.